VKTX250103C37000
- 3.38
- 0.000.00%
Viking Therapeutics Newsroom
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Year-end review of the US stock market: The seven giants continue to surge, and investors prepare for Trump 2.0.
In 2024, the US stock market is driven by the AI boom, the Federal Reserve's interest rate cuts, and strong economic growth, with the three major indices reaching new highs: the S&P 500 Index up 25% for the year, the Nasdaq Composite Index up 31% for the year, and the Dow Jones up 14% for the year; following Trump's return, a series of policies are expected to create huge waves, and the Federal Reserve's comments indicating a slowdown in interest rate cuts have already disturbed the market.
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Will Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Stocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and Bitcoin
Insider Sellers Might Regret Selling Viking Therapeutics Shares at a Lower Price Than Current Market Value
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
Why Viking Therapeutics Tumbled by More Than 10% This Week
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $109
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125